Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Santora

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 30, 2014
Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture TrialH G Bone, D W Dempster, J A Eisman, et al.
The American Journal of Medicine|November 14, 1997
Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal womenJ L Stock, N H Bell, C H Chesnut, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 5, 2002
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosisR Rizzoli, S L Greenspan, G Bone, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 27, 2010
Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effectJohn A Eisman, Henry G Bone, David J Hosking, et al.
JAMA|December 28, 2006
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trialDennis M Black, Ann V Schwartz, Kristine E Ensrud, et al.
Mabs|June 19, 2013
Expression of antibodies using single open reading frame (sORF) vector design: Demonstration of manufacturing feasibilityWendy R Gion, Rachel A Davis-Taber, Dean A Regier, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 2, 2015
Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extensionZ L Zhang, E Y Liao, W B Xia, et al.
Journal of Medicinal Chemistry|June 28, 2023
Optimization of Drug-Linker to Enable Long-term Storage of Antibody-Drug Conjugate for Subcutaneous DosingAdrian D Hobson, Jianwen Xu, Christopher C Marvin, et al.
Aging (Milan, Italy)|April 4, 2000
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study GroupT Schnitzer, H G Bone, G Crepaldi, et al.
Journal of Medicinal Chemistry|February 8, 2022
Design and Development of Glucocorticoid Receptor Modulators as Immunology Antibody-Drug Conjugate PayloadsAdrian D Hobson, Michael J McPherson, Wendy Waegell, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 30, 2014
Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture TrialH G Bone, D W Dempster, J A Eisman, et al.
The American Journal of Medicine|November 14, 1997
Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal womenJ L Stock, N H Bell, C H Chesnut, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 5, 2002
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosisR Rizzoli, S L Greenspan, G Bone, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 27, 2010
Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effectJohn A Eisman, Henry G Bone, David J Hosking, et al.
JAMA|December 28, 2006
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trialDennis M Black, Ann V Schwartz, Kristine E Ensrud, et al.
Mabs|June 19, 2013
Expression of antibodies using single open reading frame (sORF) vector design: Demonstration of manufacturing feasibilityWendy R Gion, Rachel A Davis-Taber, Dean A Regier, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 2, 2015
Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extensionZ L Zhang, E Y Liao, W B Xia, et al.
Journal of Medicinal Chemistry|June 28, 2023
Optimization of Drug-Linker to Enable Long-term Storage of Antibody-Drug Conjugate for Subcutaneous DosingAdrian D Hobson, Jianwen Xu, Christopher C Marvin, et al.
Aging (Milan, Italy)|April 4, 2000
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study GroupT Schnitzer, H G Bone, G Crepaldi, et al.
Journal of Medicinal Chemistry|February 8, 2022
Design and Development of Glucocorticoid Receptor Modulators as Immunology Antibody-Drug Conjugate PayloadsAdrian D Hobson, Michael J McPherson, Wendy Waegell, et al.
Pageof 7